Mutations in the Mycobacterium tuberculosis genome associated with genotypic MDR: dominant variants in the current (2011-2018) population of Russian strains and meta-analysis of world data

The mutations associated with resistance to rifampicin and isoniazid studied in the genome of M.tuberculosis isolated from 3,144 patients with pulmonary tuberculosis from the clinical and consulting departments of the Central TB Research Institute for the period 2011 - May 2018. The obtained results compared with the spectrum of mutations described for the worldwide population of resistant M.tuberculosis according to TBDReaMDB. The uniqueness of the world population of M.tuberculosis was shown on the specific genetic markers of resistance. The prevalence of MTB strains with the combination of mutations leading to a high level of resistance to rifampicin (rpoB 531 Ser-> Leu) and isoniazid (katG 315 Ser-> Thr(1)) were shown for Russian population of M.tuberculosis. These mutations did not adversely affect the transmissibility of the pathogen. The prevalence of these mutant variants was higher than in other regions of the world. The obtained results allow to make a conclusion about the unfavorable epidemiological situation related to the spread of MDR tuberculosis in the Russian Federation.

Микобактерии туберкулеза, лекарственная устойчивость, спектр мутаций, биологические микрочипы, Mycobacterium tuberculosis, drug resistance, mutations spectrum, biochips

1. Global tuberculosis report 2017. Geneva: World Health Organization. 2017.

2. Нечаева О.Б. Основные показатели по туберкулезу в Российской Федерации. Центральный научно-исследовательский институт организации и информатизации здравоохранения. Федеральный Центр мониторинга противодействия распространению туберкулеза. URL: http://mednet.ru/images/stories/ tb2017.pdf

3. Zhang Y., Yew W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2009; 13: 1320-30.

4. Gagneux S., Long C.D., Small P.M., Van T., Schoolnik G.K., Bohannan B.J. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006; 312: 1944-6.

5. Эргешов А., Андреевская С.Н., Ларионова, Е.Е., Смирнова Т.Г., Черноусова Л.И. Спектр мутаций в генах, ассоциированных с устойчивостью к рифампицину изониазиду и фторхинолонам, у клинических штаммов Mycobacterium tuberculosis отражает трансмиссивность мутантных клонов. Молекулярная биология. 2017; 51 (4): 595-602.

6. Андреевская С.Н., Андриевская И.Ю., Киселева Е.А., Ларионова Е.Е., Смирнова Т.Г., Черноусова Л.Н., Эргешов А.Э. Влияние мутаций, связанных с устойчивостью к рифампицину, на «фитнес» штаммов M.tuberculosis. Туберкулез и социально-значимые заболевания. 2016; 2: 33-8.

7. Sandgren A., Strong M., Muthukrishnan P., Weiner B.K., Church G.M., Murray M.B. Tuberculosis Drug Resistance Mutation Database. PLoS Med. 2009; 6(2): e1000002.